Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until ...

− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered – MONROE TOWNSHIP, N.J. & ...

Currently, postoperative prostate-specific antigen (PSA) levels are the preferred noninvasive biomarker in patient follow-ups, but sufficient criteria for predicting biochemical recurrence have not ...

Philadelphia, February 14, 2023 – Predicting the course of prostate cancer is challenging because only a fraction of prostate cancer patients experience recurrence after radical prostatectomy or ...

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is ...

Credit: Getty Images Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer. Investigators have identified ...

The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma Approximately 400,000 men are diagnosed each year with prostate cancer ...

A phase I open-label study of escalating-dose oral cyclophosphamide (CTX), docetaxel (D), zoledronic acid (ZA), and high-dose calcitriol (HDC) for castration-resistant prostate cancer (CRPC).

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

New York, NY, January 22, 2009 – Although primary prostate surgery or radiotherapy is successful in many cases of prostate cancer, some patients will suffer a recurrence of the disease, which is most ...